Kymera Therapeutics, Inc.
- KYMR
- NASDAQ
- Biotechnology
- Protein Degradation Therapy
- Small Molecule Therapeutics
- Clinical-Stage Biotech
$108.07
Today +3.14%Quote Oct 19, 2026, 08:00 PM UTC
−8.22%over the last month
Max drawdown −14.2%From 1-month high −11.5%3 months −4.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
273
Founded
2015
Market value
$8.89B
Quote Oct 19
Floor
$107.43
0.6% below price
Resistance
$110.48
2.2% above price
Price vs analyst targets
27 analysts
Lowest target
$97.00Highest target
$180.00
$97.00Highest target
$180.00
- Price $108.07
- Average target $138.20
- Analysts' target range
The price is close to the lowest analyst target. Analysts' average target sits about 28% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KYMRPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free